Global Liver Disease Treatment Industry to 2027 – Featuring AbbVie, Emergent BioSolutions and Novartis, Among Others – | Business and finance


The global liver disease treatment market reached a value of US$20.83 billion in 2021. Looking ahead, the publisher expects the market to reach a value of US$30.91 billion by 2027, growing at a CAGR of 6.50% in 2022-2027.

  • Abbott Laboratories
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Bristol-Myers Squibb Company
  • Eli Lily
  • Emergent BioSolutions Inc.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences Inc.
  • GlaxoSmithKline plc
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Viatris inc.

Keeping in mind the uncertainties of COVID-19, we continuously monitor and assess the direct and indirect influence of the pandemic. This information is included in the report as a major market contributor.

The liver is a vital organ in the human body that performs important functions, such as storing vitamins and nutrients, removing harmful substances from the blood, and maintaining the proper balance of chemicals in the body. Cancer, hepatitis, autoimmune diseases and genetic disorders are common liver diseases. These diseases are usually caused by infections, genetics, obesity, diabetes and immune system abnormalities. Some of the widely used therapeutic techniques for liver diseases include vaccines, chemotherapy, antiviral drugs, immunoglobulins, corticosteroids, and immunosuppressants. The treatment of liver disease helps in the excretion of cholesterol and hormones, increases the production of bile and the activation of enzymes.

The growing geriatric population, which is susceptible to various chronic diseases including liver diseases, across the globe is one of the major factors driving the growth of the market. Changing dietary habits and sedentary lifestyles are driving the growth of the market.

Additionally, the growing prevalence of fatty liver due to high cholesterol, obesity, hypertension (high blood pressure), and diabetes is driving the growth of the market. Moreover, various technological advancements, such as the development of bioartificial liver, are providing impetus for the growth of the market. It uses regenerated liver cells to replace liver functions and is widely used for patients with acute liver failure.

With this in mind, the rapid adoption of antiviral drugs, because they are safe and effective, help suppress the hepatitis B virus and help reduce the risk of developing cirrhosis and hepatocellular carcinoma, has a positive impact on the market growth. Apart from this, increasing research and development (R&D) activities, significant growth in the healthcare sector, and implementation of various government initiatives to promote public health are creating a positive outlook for the market.

Answers to key questions in this report:

  • How has the global liver disease treatment market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global liver disease treatment market?
  • What are the main regional markets?
  • What is the market breakdown by type of treatment?
  • What is the market breakdown by disease type?
  • What is the market breakdown by end user?
  • What are the different stages of the industry value chain?
  • What are the key drivers and challenges in the industry?
  • What is the structure of the global liver disease treatment market and who are the key players?
  • How competitive is the industry?

5 Global Liver Disease Treatment Market

6 Market Breakdown by Treatment Type

7 Market Breakdown by Disease Type

8 Market Breakdown by End User

9 Market Breakdown by Region

12 Analysis of the five forces of carriers

14.3 Profiles of Key Players

Laura Wood, Senior Press Officer

For EST business hours, call 1-917-300-0470

For US/CAN call toll free 1-800-526-8630

For GMT office hours call +353-1-416-8900


SOURCE: Research and Markets

Copyright BusinessWire 2022.

PUBLISHED: 08/04/2022 09:16 / DISK: 08/04/2022 09:16

Copyright BusinessWire 2022.

Comments are closed.